NBIX:NASDAQ
Neurocrine Biosciences, Inc
USD 143,47
arrow_downward
-1,40%(-2,04) 1D
USD 143,47
0,00% (0,00)
bedtimeAfter hours
Closed: 7 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
USD 145,33
High
USD 145,88
Low
USD 143,21
Mkt. cap
14,58 mjd
Avg. vol.
1,27 m
Volume
1,14 m
P/E ratio
21,03
52-wk high
USD 186,12
52-wk low
USD 122,14
EPS
USD 6,82
Beta
0,40
Shares outstanding
101,65 m
No. of employees
2 k
Open
USD 145,33
High
USD 145,88
Low
USD 143,21
Mkt. cap
14,58 mjd
Avg. vol.
1,27 m
Volume
1,14 m
P/E ratio
21,03
52-wk high
USD 186,12
52-wk low
USD 122,14
EPS
USD 6,82
Beta
0,40
Shares outstanding
101,65 m
No. of employees
2 k
News stories
From web sources and news partners
Stock Titan
·
1 uur gelede
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts.
Simply Wall Street
·
12 uur gelede
Neurocrine Biosciences (NBIX) After New VYKAT XR Data Why The Undervalued Narrative Persists
AD HOC NEWS
·
19 uur gelede
Neurocrine Biosciences stock fell 1.4 percent before research event
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2,5 k
Founded1992
HeadquartersSan Diego, Kalifornië, Verenigde State van Amerika
Sector-
Websiteneurocrine.com